Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans.
Anand
R
R
Clinical Research Department, F. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Wesnes
K A
KA
D001549:Benzamides / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000378:metabolism; D004311:Double-Blind Method; D006801:Humans; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide